Sex-related differences in the association between septal wall thickness and survival.

Hypertrophic cardiomyopathy Septal hypertrophy Sex-related differences

Journal

International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 24 03 2024
revised: 08 05 2024
accepted: 11 05 2024
medline: 7 6 2024
pubmed: 7 6 2024
entrez: 7 6 2024
Statut: epublish

Résumé

In many conditions characterised by septal hypertrophy, females have been shown to have worse outcomes compared to males. In clinical practice and research, similar cutoff points for septal hypertrophy are still used for both sexes. Here, we explore the association between different cutoff points for septal hypertrophy and survival in relation to sex. We performed a retrospective analysis of consecutive patients undergoing echocardiography between March 2010 and February 2021 in a large tertiary referral centre. A total of 70,965 individuals were included. Over a mean follow-up period of 59.1 ± 37 months, 9631 (25 %) males and 8429 (26 %) females died. When the same cutoff point for septal hypertrophy was used for both sexes, females had worse prognosis than males. The impact of septal hypotrophy on survival became statistically significant at a lower threshold in females compared to males: 11.1 mm (HR 1.13, CI 95 %:1.03-1.23, p = 0.01) vs 13.1 mm (HR 1.21, CI 95 %: 1.12-1.32, p < 0.001). However, when indexed wall thickness was used, the cutoff points were 6 mm/body surface area (BSA) (HR 1.08, CI 95 %: 1-1.18, p = 0.04) and 6.2 mm/BSA (HR 1.07, CI 95 %: 1-1.15, p = 0.05) for females and males, respectively. Septal hypertrophy is associated with increased mortality at a lower threshold in females than in males. This may account for the worse prognosis reported in females in many conditions characterised by septal hypertrophy. Applying a lower absolute value or using indexed measurements may facilitate early diagnosis and improve prognostication in females.

Sections du résumé

Background UNASSIGNED
In many conditions characterised by septal hypertrophy, females have been shown to have worse outcomes compared to males. In clinical practice and research, similar cutoff points for septal hypertrophy are still used for both sexes. Here, we explore the association between different cutoff points for septal hypertrophy and survival in relation to sex.
Methods and results UNASSIGNED
We performed a retrospective analysis of consecutive patients undergoing echocardiography between March 2010 and February 2021 in a large tertiary referral centre. A total of 70,965 individuals were included. Over a mean follow-up period of 59.1 ± 37 months, 9631 (25 %) males and 8429 (26 %) females died. When the same cutoff point for septal hypertrophy was used for both sexes, females had worse prognosis than males. The impact of septal hypotrophy on survival became statistically significant at a lower threshold in females compared to males: 11.1 mm (HR 1.13, CI 95 %:1.03-1.23, p = 0.01) vs 13.1 mm (HR 1.21, CI 95 %: 1.12-1.32, p < 0.001). However, when indexed wall thickness was used, the cutoff points were 6 mm/body surface area (BSA) (HR 1.08, CI 95 %: 1-1.18, p = 0.04) and 6.2 mm/BSA (HR 1.07, CI 95 %: 1-1.15, p = 0.05) for females and males, respectively.
Conclusions UNASSIGNED
Septal hypertrophy is associated with increased mortality at a lower threshold in females than in males. This may account for the worse prognosis reported in females in many conditions characterised by septal hypertrophy. Applying a lower absolute value or using indexed measurements may facilitate early diagnosis and improve prognostication in females.

Identifiants

pubmed: 38846157
doi: 10.1016/j.ijcha.2024.101427
pii: S2352-9067(24)00093-9
pmc: PMC11152968
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101427

Informations de copyright

© 2024 The Author(s).

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Shafik Khoury (S)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Lior Zornitzki (L)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Michal Laufer-Perl (M)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Raghav T Bhatia (RT)

Cardiovascular Clinical Academic Group, St. George's, University of London, St. George's University Hospitals NHS Foundation Trust, United Kingdom.

Sarandeep Marwaha (S)

Cardiovascular Clinical Academic Group, St. George's, University of London, St. George's University Hospitals NHS Foundation Trust, United Kingdom.

Maite Tome (M)

Cardiovascular Clinical Academic Group, St. George's, University of London, St. George's University Hospitals NHS Foundation Trust, United Kingdom.

Yoav Granot (Y)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Moran Gvili Perelman (M)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Ido Avivi (I)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Yacov Shacham (Y)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Yishay Szekely (Y)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Shmuel Banai (S)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Aviram Hochstadt (A)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Nir Flint (N)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Yan Topilsky (Y)

Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Tel Aviv University, Tel Aviv, Israel.

Classifications MeSH